Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director · See Remarks | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 709,153 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 58,061 · Balance 709,425 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F2: The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 2 · 2026-10-05 · Sale · Disposed 272 · Balance 709,153 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F3: The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
F2: The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 21:11 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 272 | $13.61 | $3,702.03 |
DisclosureSEC source: 0001193125-26-417068 · ownership.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 709,153 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F3 · price: The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 21:11 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 58,061 | $12.92 | $750,235.21 |
DisclosureSEC source: 0001193125-26-417068 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 709,425 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F2 · price: The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 21:13 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 58,333 | $13.90 | $811,003.70 |
DisclosureSEC source: 0001193125-26-393243 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 767,486 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F2 · price: The transaction was executed in multiple trades in prices ranging from $13.43 to $14.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:06 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001193125-26-361096 · ownership.xml · derivative · entry 4 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,500 Underlying: Common Stock · 50,000 shares Expires 2035-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:06 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 25,927 | $16.42 | $425,651.34 |
DisclosureSEC source: 0001193125-26-361096 · ownership.xml · nonDerivative · entry 3 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 825,819 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F3 · price: The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:06 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 43,149 | $15.36 | $662,621.93 |
DisclosureSEC source: 0001193125-26-361096 · ownership.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 851,746 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F2 · price: The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:06 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 50,000 | $4.14 | $207,000.00 |
DisclosureSEC source: 0001193125-26-361096 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 894,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. Read SEC document |
| August 04, 2026 Filed Aug 5, 2026 20:10 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 26,842 | $10.23 | $274,596.34 |
DisclosureSEC source: 0001193125-26-335115 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 844,895 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F2 · price: The transaction was executed in multiple trades in prices ranging from $10.07 to $10.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 20:45 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 12,415 | $10.05 | $124,722.33 |
DisclosureSEC source: 0001193125-26-333014 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 871,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F2 · price: The transaction was executed in multiple trades in prices ranging from $10.00 to $10.1250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 21:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 442 | $12.84 | $5,673.29 |
DisclosureSEC source: 0001834021-26-000004 · ownership.xml · nonDerivative · entry 3 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 884,152 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F4 · price: The transaction was executed in multiple trades in prices ranging from $12.82 to $12.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 21:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 15,283 | $12.01 | $183,559.53 |
DisclosureSEC source: 0001834021-26-000004 · ownership.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 884,594 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F3 · price: The transaction was executed in multiple trades in prices ranging from $11.575 to $12.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 09, 2026 Filed Jul 14, 2026 21:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 42,608 | $12.87 | $548,177.48 |
DisclosureSEC source: 0001834021-26-000004 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 899,877 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F2 · price: The transaction was executed in multiple trades in prices ranging from $12.68 to $13.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:19 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 114,746 | $10.47 | $1,200,851.31 |
DisclosureSEC source: 0001834021-26-000002 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 942,485 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F2 · price: The transaction was executed in multiple trades in prices ranging from $10.00 to $10.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:48 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,922 | $10.02 | $19,257.86 |
DisclosureSEC source: 0001193125-26-253740 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,057,231 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. F2 · price: The transaction was executed in multiple trades in prices ranging from $10.00 to $10.055, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:30 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001193125-26-129156 · ownership.xml · derivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:58 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 267,500 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000950170-25-036688 · ownership.xml · derivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,500 Underlying: Common Stock · 267,500 shares Expires 2035-03-05 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 21:46 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,270 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0000950170-24-083303 · ownership.xml · derivative · entry 5 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,730 Underlying: Common Stock · 1,270 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024. F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 21:46 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 11,653 | $0.00 Strike: $14.42 | $0.00 |
DisclosureSEC source: 0000950170-24-083303 · ownership.xml · derivative · entry 4 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 565,417 Underlying: Common Stock · 11,653 shares Expires 2033-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 21:46 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 12,923 | $22.49 | $290,598.21 |
DisclosureSEC source: 0000950170-24-083303 · ownership.xml · nonDerivative · entry 3 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,059,153 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024. F2 · price: The transaction was executed in multiple trades in prices ranging from $22.05 to $23.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 21:46 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,270 | $15.78 | $20,040.60 |
DisclosureSEC source: 0000950170-24-083303 · ownership.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,072,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 21:46 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 11,653 | $14.42 | $168,036.26 |
DisclosureSEC source: 0000950170-24-083303 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,070,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:07 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 12,930 | $0.00 Strike: $14.42 | $0.00 |
DisclosureSEC source: 0000950170-24-077944 · ownership.xml · derivative · entry 3 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 577,070 Underlying: Common Stock · 12,930 shares Expires 2033-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:07 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 12,930 | $23.10 | $298,711.45 |
DisclosureSEC source: 0000950170-24-077944 · ownership.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,059,153 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024. F2 · price: The transaction was executed in multiple trades in prices ranging from $22.69 to $23.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:07 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 12,930 | $14.42 | $186,450.60 |
DisclosureSEC source: 0000950170-24-077944 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,072,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 01:22 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 92,001 | $27.13 | $2,495,821.53 |
DisclosureSEC source: 0000950170-24-014091 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,059,153 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $26.75 to $27.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:59 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 5,696 | $18.41 | $104,851.40 |
DisclosureSEC source: 0000950170-24-007477 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,151,154 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $18.06 to $18.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 21:19 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 133 | $20.11 | $2,673.97 |
DisclosureSEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 5 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,156,850 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023. F6 · price: The transaction was executed in multiple trades in prices ranging from $20.09 to $20.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 21:19 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 28,104 | $19.56 | $549,804.17 |
DisclosureSEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 4 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,156,983 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023. F5 · price: The transaction was executed in multiple trades in prices ranging from $19.085 to $20.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:19 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 40,732 | $20.31 | $827,201.75 |
DisclosureSEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 3 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,185,087 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $20.02 to $20.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 18, 2023 Filed Jan 8, 2024 21:19 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 4,702 | $18.13 | $85,242.56 |
DisclosureSEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,225,819 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $17.77 to $18.525, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 15, 2023 Filed Jan 8, 2024 21:19 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 28,632 | $17.27 | $494,431.69 |
DisclosureSEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,230,521 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $17.00 to $17.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 590,000 | $0.00 Strike: $14.42 | $0.00 |
DisclosureSEC source: 0000950170-23-070013 · ownership.xml · derivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590,000 Underlying: Common Stock · 590,000 shares Expires 2033-12-10 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:09 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GiftCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-023022 · form4.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trusts Disclosed balance after: 600,000 F1 · kind: Reflects gifts of shares by the Reporting Person to irrevocable trusts established for the benefit of the Reporting Person's children. The Goldman Sachs Trust Company of Delaware is the Trustee of such trusts. Read SEC document |
| May 02, 2023 Filed May 5, 2023 00:09 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GiftCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-023022 · form4.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,259,153 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 00:56 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 16,449 | $20.22 | $332,664.58 |
DisclosureSEC source: 0001567619-23-003706 · doc1.xml · nonDerivative · entry 3 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,859,153 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $19.96 to $20.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:56 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 907 | $21.49 | $19,491.16 |
DisclosureSEC source: 0001567619-23-003706 · doc1.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875,602 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $21.40 to $21.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:56 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 17,090 | $20.93 | $357,717.63 |
DisclosureSEC source: 0001567619-23-003706 · doc1.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,876,509 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $20.35 to $21.305, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 01:24 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 222,000 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0001567619-23-003008 · doc1.xml · derivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,000 Underlying: Common Stock · 222,000 shares Expires 2033-02-09 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 00:57 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 8,625 | $20.19 | $174,126.68 |
DisclosureSEC source: 0001567619-23-001163 · doc1.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,893,599 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $20.01 to $20.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 00:57 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 10,899 | $20.03 | $218,347.30 |
DisclosureSEC source: 0001567619-23-001163 · doc1.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,902,224 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $19.83 to $20.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 22:56 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 26,349 | $23.39 | $616,205.62 |
DisclosureSEC source: 0001567619-22-021815 · doc1.xml · nonDerivative · entry 4 Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,913,123 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $23.19 to $23.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 22:56 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 27,595 | $22.66 | $625,371.69 |
DisclosureSEC source: 0001567619-22-021815 · doc1.xml · nonDerivative · entry 3 Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,939,472 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $22.18 to $23.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 22:56 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,500 | $24.13 | $36,199.05 |
DisclosureSEC source: 0001567619-22-021815 · doc1.xml · nonDerivative · entry 2 Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,967,067 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $24.07 to $24.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 22:56 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 31,433 | $23.56 | $740,567.77 |
DisclosureSEC source: 0001567619-22-021815 · doc1.xml · nonDerivative · entry 1 Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,968,567 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $23.04 to $24.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001567619-22-002466 · doc1.xml · derivative · entry 2 Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $41.66 | $0.00 |
DisclosureSEC source: 0001567619-21-005967 · doc1.xml · derivative · entry 1 Kirn David · CIK 0001834021 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-07 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 8, 2021 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.